๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT ยท Real-Time Price ยท USD
28.45
-0.04 (-0.16%)
Nov 18, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Reached profitability as clonoSEQ volume grew 46% YoY. Guideline updates, broader community and EMR adoption, expanded testing across the patient journey, and pharma demand support further growth.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Kick it off. Welcome, everyone. I'm Tycho Peterson from the Life Science team. It's my pleasure to introduce Adaptive Biotechnologies. Welcome, Chad. Why don't we maybe just quick recap of the quarter, if you're good to start there. 46% clonoSEQ growth, 44% core MRD revenue growth. Just talk about the momentum and how you think about that heading into 2027.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. Give me one second. Let's get these guys moving. Let's go. All right. Yeah, great quarter. Thrilled to see the results. Really three things that I can point to. The first is we achieved company-wide profitability, and at the end of the day, that's just a meaningful milestone for us, actually a meaningful milestone for any company in the diagnostic space, as we know. But it also, it just gives us a lot more flexibility. Number two, just, yeah, you mentioned it, couldn't be more pleased by the volume growth, again, a 46% year-over-year, 10% sequential growth. But if you look at our DLBCL grew 20% in the quarter, our largest indication, multiple myeloma, 11%, which is great.

Then third, and this is just a long-term tailwind for the business and impacts so many different areas, both currently and in the future, is if you look at two really significant updates. One is the NCCN guideline update, which I'm sure we'll go kind of more into. Then the second, and particularly meaningful, is definition of cure in multiple myeloma. I was just telling this story to one-on-one investor conference, but at the end of the day, we had one of our clinician,

KOLs , was crying in the hallway, because he'd been working for his entire life on multiple myeloma and said never did he think that in his lifetime he would see that there was a definition of, that A, patients could technically be cured of this horrible disease, and then B, from our standpoint, that we had the test to be able to, that was really pointed at by the International Myeloma Working Group to say, "This is what defines a cure.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Maybe since you opened up the door on guidelines, just talk a little bit about practically, what are you seeing in the community channel, and how long does that take to really influence behavior and ordering patterns?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah, I think what was so impactful from the guidelines is the specificity, kind of for the first time, about talking and really being prescriptive of how you use our tests in the patient care continuum. After CAR T therapy, after a transplant, after induction, after consolidation therapy, all those are super important. But to me, I think what was kind of most meaningful is really this whole new phase of the patient care continuum in the maintenance setting, where it's specifically called out using a 10 to the six assay in the maintenance setting. That really opens up the door for us to kind of this, after, if you consider kind of the active treatment phase, now there's this whole new kind of maintenance phase, and that's what really, I think we're super excited about. We'll talk about later how that plays into reimbursement.

Your question on the community is, if you look at the community oncologists, why this is kind of particularly important for us, kind of from a business standpoint, is doctors in the community are really driven by guidelines. They want to be more told when to use a test. Having the guidelines be prescriptive really means that they can go point exactly to the guidelines, and our reps can go in and say, "You should be using it X, Y, Z time points," and kind of plan out with the clinician when they're going to be treating that patient and have them on that cadence, which has been great. Now, typically we say that the lag between getting a guideline update and really the uptake in the community is 9-12 months.

In this particular case, given the strength of the guidelines, we may see kind of a quicker uptake than that kind of 9-12 month period.

Tycho Peterson
Managing Director of Global Equities, Jefferies

You flagged the definition of cure, a negativity over a five-year treatment window. Maybe just talk a little bit about how that maybe changes the market overall in terms of repeat testing.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. I started down this path, so let me kind of finish it. If you consider the patient care continuum, we look at it in three phases. The active treatment phase, which is the ID test plus three other tests, which is induction, consolidation, and potentially transplant decision. That is kind of the first bundle that we have by Medicare. Then we have kind of the maintenance therapy, which is, again, without promises, but we have said we have submitted for a new bundle for five tests. Then we consider that definition of cure to really play into the third area, which is recurrence monitoring. So when a patient is off treatment, then they would get a test at a cadence of annually or more to determine if they can detect disease relapse kind of before clinical presentation.

Overall, we look at the opportunity to test a patient over their life cycle for these 12 to 15 tests. Kind of four during active treatment, five during maintenance, that is nine, and then another kind of three to five tests during recurrence.

Tycho Peterson
Managing Director of Global Equities, Jefferies

You expect to submit CLL for recurrence monitoring for first half of next year. Just talk about the evidence package supporting the submission, and does that become a template for longitudinal coverage across other indications?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. Just first thing to remember, we actually got our first recurrence monitoring claim in MCL, so we do effectively have a template for how to do this. In CLL, we are just waiting for kind of long-term patient follow-ups and for kind of the data to solidify before we are submitting that package. What is exciting is we have really made some significant investments in our RWD, our real-world data capabilities, which, by the way, we were able to use for the submission package on kind of recurrence monitoring, excuse me, for maintenance therapy bundle in multiple myeloma. We also believe that we will be able to use this to also submit in the second half for multiple myeloma recurrence monitoring to kind of complete that third phase. Net-net, we are just waiting on some kind of additional data in CLL and additionally plan to submit in multiple myeloma.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Maybe just talk a little bit about the ASP roadmap. You have talked about $1,700-$1,800 longer term. You will end at this year about $1,400. Just talk about the bridge to the remaining $300-$400.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. If I look at the bridge in kind of percentage term, I would put kind of 50% of the bridge from kind of $1,380 now to the effectively $1,700-$1,800. I would put 50% of that based on Medicare changes and updates, again, maintenance bundle, recurrence monitoring, et cetera. I would put 20% of that bridge, the additional 20% into, call it kind of policy or coverage expansions. 20% I would put into re-contracting with existing payers, and then the other 10% I would spread between Medicare and all the internal efforts we are doing on revenue cycle management initiatives, such as kind of the automation of prior authorization, the AI capabilities for the appeals process. Really, all this goes to kind of time to cash and kind of the percentage of your wins on appeals. So that gets you to kind of 100%.

Probably not exact, but that is how we see the bridge.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Blood versus marrow, it has been kind of a debate for a while here. Are you seeing evidence in physicians who have been reluctant to order bone marrow becoming more willing on the blood side?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. Absolutely. I would say this. About 51% overall of our tests are done in blood. However, you got to account for the fact that certain of our tests are only done in blood, like DLBCL and CLL. But what we are seeing that we are kind of excited about is in more specific to the blood versus marrow conversation in multiple myeloma, you now have kind of roughly about 35% of our tests that are now being done in blood. And you have had a very significant increase kind of year-over-year, and even quarter-over-quarter, we are continuing to see kind of increases in the willingness to test in the blood.

Tycho Peterson
Managing Director of Global Equities, Jefferies

And maybe circling back in community, where are we kind of in that adoption curve on the community side, and how does testing frequency in blood utilization compare on community?

Chad Robins
CEO, Adaptive Biotechnologies

Well, overall, if you look at the contribution of our overall, it is about 37% of our orders are coming from the community. The math is roughly kind of 60%, 65%, for 65% of blood cancer patients are treated in the community. So, I think we have a long way to go. Both the academic medical institutions and the community, they are both growing. It is just community is growing at kind of 15%, whereas kind of academic medical centers are growing at 7% this quarter-over-quarter. So that gets us to our blended average of, not about, the 10% quarter-over-quarter sequential growth. So while they are both growing, community is growing at a faster clip. So there is a tremendous amount of growth ahead of us in the community.

Again, this going back to, not to repeat myself, but guidelines are so important for the community that you kind of have this built-in tailwind. The second thing I would say about the community that we're kind of super excited about is we, for our EMR integrations, we put in a kind of Flatiron Health, and the OncoEMR system has the ability to do repeat ordering. What we're seeing is 75% of clinicians are clicking on this repeat ordering function. Of that, 78%, we've got like now three-quarters worth of data, 78% of those patients are in compliance. You could schedule a test, but the patient has to come in again and fulfill their appointment. We're seeing a tremendously high rate.

As I think to kind of the tailwinds and kind of this built-up or pent-up demand going into 2027, we already kind of have a little bit of a window into our pipeline in the clinic. I mean, you always have that in pharma, but in the clinic, we also have that because of this kind of serial ordering kind of functionality.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Then maybe just stepping back on EMR, I think half the orders in 3Q were for clonoSEQ, where you've built into the EMR. Where do you see that going? Talk about the lift you get when you do an EMR implementation.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. About half are now, and we see that number could go up to kind of 70%, 80%. It's going to take some time to get there, but we're super excited about kind of EMR integrations. I've talked a little bit about the lift that we're seeing from Flatiron serial ordering, but there's another aspect of EMR integrations. I mean, at the end of the day, but like even in academic medical institutions, 15 to 20 of our top largest accounts are now integrated. You may say, "Oh, well, you're kind of gotten that kind of boost from EMR integration." That's not the case at all, because what we're really focused on is optimizations.

We kind of have this SWAT team that goes in once an account is integrated and say, "Okay, how can we really educate the clinicians, the nurse practitioners, the entire team on how to really, really use kind of the EMR integration?" Great examples of that, like City of Hope, we've seen kind of tremendous 20% quarter-over-quarter growth from an optimization. Even in Epic, with Duke, we saw a 22% quarter-over-quarter growth. We're seeing that in NewYork-Presbyterian as well. Yeah, over and over, like, this is, we're putting more resources into really figuring out how to go in and do this.

The other thing that has happened actually with guidelines tying this to EMR integrations is we've had institutions who've been sitting on the sidelines for years and saying, not for years, but since we started doing this, and saying, "Hey, we're not going to do an EMR." You got to get the IT people in, you got to get all the doctors that all want to do this. Since the guidelines update in September, for two great examples, UNC and UCSF have come to us and said, "Hey, we're ready. Guidelines, our doctors are asking for this test. We got to get this integrated into the EMR system." That's kind of how these things all work together.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Let's hit on margins quickly. I mean, you talked about the profitability, but MRD margins, 74% in 3Q. You talked about 75% by the end of the year. Maybe just talk about some of the efficiencies you've driven and where do margins go from here?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. We also have a lot of room to go in our margins. As you know, we did the NovaSeq X implementation last year on the clinical side. What is not known is, right now when we do a sequencing run, we multiplex and put about 300 samples at a time on there. We can get over 500 samples on each run. The largest cost for us of delivering the test is the sequencing. So think about kind of the leverage we can get just from increasing kind of the number of tests we put on each sequencing run. The second thing to point out in terms of kind of margins is that our pharma business, we have not converted over to the NovaSeq X yet. They're all still running on NextSeq.

So we will, by, call it the end of this year, convert all the pharma business over to NovaSeq X. Then the third component of really kind of the margin expansion is, as your ASP goes up, you are obviously going to get a boost in your margins. So net-net, I mean, 80% gross margins are certainly in our sight.

Tycho Peterson
Managing Director of Global Equities, Jefferies

And maybe just talk on the re-acceleration you have seen in pharma, 25% growth I think this year, increased use of MRD in regulated and interventional multiple myeloma studies. Just talk about the momentum on pharma.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. I mean, this has been a banner year for pharma. I mean, not only from a revenue standpoint, but our bookings have even exceeded our internal projections. A lot of that, like, remember the ODAC decision to have kind of the first new primary endpoint in 10 years in multiple myeloma, that was two and a half years ago, but the FDA kind of codified that decision in terms of its guidance that came out in January. That certainly, our multiple myeloma kind of franchise in pharma has been. Not only have we signed new studies, but existing studies have really expanded with more time points per patient in those studies. So that is just kind of in myeloma itself, we now have kind of 19 studies in myeloma where primary endpoint.

Secondly, in terms of the halo effect that we are seeing in other indications, like we are working with different kind of societies, academic bodies, et cetera, in other disease states to get them as a kind of primary endpoint, particularly CLL, MCL, et cetera. Pharma wants to make sure that they are on the kind of cutting edge of that, and they are incorporating MRD into their trials in advance of that. So we are seeing really a nice lift, particularly our CLL business this year in pharma has done really well. So has our ALL business. So, really across the board. The other thing I will say is, historically, we have talked about the pharma business being kind of a 12%-15% potential growth rate to put on it. We are kind of revising that to say we are comfortable with putting a 15% CAGR on there.

We are going to obviously beat that this year, but we want to make sure that we are being on the conservative side.

Tycho Peterson
Managing Director of Global Equities, Jefferies

I guess if regulators broaden the acceptance of MRD for accelerated drug development, does that change kind of the outlook on pharma, thinking about companion diagnostics opportunities?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. I mean, it does. I mean, remember, we are the only FDA-approved test right now. So, as you look at kind of companion diagnostic opportunities, and if they are going to kind of dictate to a company to do it, we are certainly in the driver's seat with respect to CDx tests.

Tycho Peterson
Managing Director of Global Equities, Jefferies

You know, thinking about just the clinical to commercial flywheel, is there a kind of a rule of thumb, pharma-sponsored trials eventually translating into kind of routine clinical use once the drug launches? How do you think about that flywheel?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. That's a really good question, and actually something we wound up getting a lot of, having a lot of discussion on today. If you look at kind of the multiple myeloma franchise itself, you're talking about a $20 billion kind of annual market multiple myeloma drugs. It is absolutely creating this flywheel. If you just look at kind of our potential TAM and the necessity of testing MRD for all these patients that are going to be on, just in multiple myeloma alone, on these drugs.

One is, if your test is being used in the clinical trial, not only is it the investigators who are in the academic KOLs, but as this goes into the clinic and you're using those sets of drugs, or you're switching kind of between drugs or figuring out the ones that work, you're going to be using our tests throughout the patient care continuum, whether it's in the active treatment phase or whether you're looking at kind of titrating your in maintenance therapy. All of those therapies kind of work hand in hand with our tests in the clinic. Again, it's probably one of the most underappreciated aspects of the business. And we've been talking about it for years, but we're actually seeing that flywheel start to accelerate.

Tycho Peterson
Managing Director of Global Equities, Jefferies

It's a big year for you guys strategically, the separation path on Immune Medicine by the end of the year. Just talk about the different options here, sales, spin, and how you think about the impact on MRD's cost profile post that.

Chad Robins
CEO, Adaptive Biotechnologies

Yeah. Let's see. Make a couple comments here. One is, we have been generating a proprietary dataset that I would argue is maybe one of the most important datasets in immunology in the world, and we've been generating this for many years now. I'd say this, the reason I put the many years on there is because we've been generating this data in advance of AI, right? And now it just happens to be that now that AI has come, the value of this data overall has gone up. And why do I say that? There's a couple things that have happened. One is, a couple years ago, the AlphaFold paper came out, and AlphaFold won the Nobel Prize for protein folding.

That was a big light bulb come on to say, "Wow, it's possible to use kind of this, a lot of data to solve an important problem in immunology." These guys won the Nobel Prize. So we went around and figured out how many data points, what's the next big problem in immunology? It was protein-protein binding, meaning TCR to antigen binding. That's the map that we were creating that we started with Microsoft in 2018. Then we did a deal with Genentech for personalized cell therapy, where we were trying to develop this in silico model to be able to predict the T-cell receptor that could be used as a therapy. That really catalyzed this effort. Then Genentech, we were doing a great, really a nice job developing the dataset, and we had a lot of T-cells that were IND-ready to go.

This wasn't even on the personalized side. But Genentech kind of walked away from the program because they had a reorg and moved out of cell therapy. But we said, "You know what?" Or my brother did. I said, "You know what? We're going to do this anyway. Screw it. We need to develop this dataset." So imagine if instead of, and I should also say, AlphaFold was built on 50 years of public data. So imagine if you had an AlphaFold-like solution that was built on proprietary data and you owned it. So imagine if Google DeepMind actually owned AlphaFold. That is essentially what the Immune Medicine opportunity is. Okay, so I'll say that first. Now, the second thing I'll point to is my goal, you asked about what the options are.

The options are, one, we could go sell this massive, but when I say massive, if you look at all the data in the public literature combined that connects T-cell receptors to antigens, it may be about 50,000. We've generated 8 million. So it's just a different scale. So what we could do is we could go, as we know, because of AI, the frontier labs are very interested in data. We could go sell it. Just like we could have sold clonoSEQ a few years ago and not gotten what I thought was real value, we could go sell this. I don't think we would get the value that it ultimately is going to become. So that's one option. We could do that.

The second option, which we could do and which we're actively assessing is, what if our Adaptive shareholders could have an ongoing stake in a new entity with new dedicated capital, but didn't have to use Adaptive's balance sheet? I think that would be amazingly accretive to Adaptive and our shareholders. So that's another area that we're pursuing. Again, we are committed to providing additional updates that we said at the JP Morgan Conference, so I would keep the eye peeled for that. Now, the last component or part of your question is, okay, what happens? So there will be some kind of additional stranded costs from spinning out or selling the business that I'll call the base business, our diagnostics business will take on. But even with that, we will be profitable, HoCo, even taking on the additional costs.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Maybe just in the closing minute or two here, what is it you think that the Street's kind of missing more broadly? I think people appreciate volume growth, the ASP path, maybe some of the margin leverage, but what do you think is kind of lost among investors today as they think about Adaptive?

Chad Robins
CEO, Adaptive Biotechnologies

Yeah, I mentioned earlier, I think kind of the, maybe the, well, two things. One is what, both I mentioned, but I will highlight them again just as a summary. The first is the value of our data, I think, is underappreciated, and hopefully we can show how important it is. We have an upcoming publication coming out that I think is going to show in a disease state that is going to be very, very interesting and going to be eye-opening. So the value of the data that we are creating on the Immune Medicine side. But on the MRD side, it is really the flywheel between pharma.

I think it is underappreciated how many hematologic malignancy drugs are being developed in these indications and the number of time points across the patient care continuum that we are going to then, that is going to translate into testing in the clinic.

Remember, like, we have, right now, what we are doing in terms of number of time points per patient in the clinic, we think with the new guidelines, with the new definition of cure, that we are going to be able to have a really, really nice expansion to be able to become standard of care throughout active treatment phase, throughout maintenance phase, and throughout recurrence monitoring, where this will truly be a tool to guide clinical intervention and decisions, not just in multiple myeloma, but in ALL, CLL, DLBCL, and mantle cell to come.

Tycho Peterson
Managing Director of Global Equities, Jefferies

Awesome. We are out of time. We will leave it at that. Thanks.